These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36744395)

  • 1. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
    Brown ZJ; Ruff SM; Pawlik TM
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging molecular therapeutic targets for cholangiocarcinoma.
    Ilyas SI; Gores GJ
    J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 4. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
    Ang C
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment for cholangiocarcinoma.
    Adeva J; Sangro B; Salati M; Edeline J; La Casta A; Bittoni A; Berardi R; Bruix J; Valle JW
    Liver Int; 2019 May; 39 Suppl 1():123-142. PubMed ID: 30892822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways and targeted therapy in cholangiocarcinoma.
    Dabney RS; Khalife M; Shahid K; Phan AT
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
    Ruff SM; Roychowdhury S; Pawlik TM
    Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
    Ilyas SI; Borad MJ; Patel T; Gores GJ
    Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
    Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
    Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
    Borger DR; Zhu AX
    Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L; Lowery M
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.